Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 6Phase 1 6Phase NA 2Phase 3 2

Status

Recruiting 30Completed 24Unknown 15Not yet recruiting 8Active not recruiting 6Withdrawn 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Multiple Myeloma 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Injections × Clear all
NCT06301308 2024-04-24

A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial

Second Xiangya Hospital of Central South University

Phase 3 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT04288765 2021-07-09

Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Grupo Cooperativo de Hemopatías Malignas

Phase 3 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡